リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Early glottic cancer treatment with concurrent chemoradiotherapy with once-daily orally administered S-1」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Early glottic cancer treatment with concurrent chemoradiotherapy with once-daily orally administered S-1

Takase, Yuuki Itoh, Yoshiyuki Ohtakara, Kazuhiro Kawamura, Mariko Ito, Junji Oie, Yumi Ono, Tamami Sasaki, Yutaro Nishida, Ayumi Naganawa, Shinji 名古屋大学

2021.05

概要

Glottic carcinoma is the most common laryngeal cancer. The outcomes for T1 bulky Glottic carcinoma and T2N0 Glottic carcinoma after radiation therapy alone are unsatisfactory. This study was conducted to evaluate the efficacy and safety of unique concurrent chemoradiotherapy regimen using S-1 for early glottic cancer. Concurrent chemoradiotherapy consisted of 60 Gy in 30 fractions with once-daily, orally administered S-1 exclusively within three to six hours prior to each irradiation. Twenty-one consecutive patients treated with this regimen were retrospectively reviewed. Initial complete remission was achieved in all patients without any subsequent local and/or regional recurrences to the last follow-up. The 4-year local control, overall survival, and disease-free survival rates were all 100%. No significant toxicities were observed, except for three cases with Grade 3 acute dermatitis.This regimen is highly effective and well-tolerated, and these results encourage further research to long-term efficacy and functional preservation.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1 Laryngeal Cancer Treatment (Adult) (PDQ®)–Health Professional Version - National Cancer Institute. https://www.cancer.gov/types/head-and-neck/hp/adult/laryngeal-treatment-pdq. Accessed March 2, 2020.

2 Forastiere AA, Ismaila N, Lewin JS, et al. Use of larynx-preservation strategies in the treatment of laryngeal cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2018;36(11):1143–1169. doi:10.1200/JCO.2017.75.7385.

3 Mendenhall WM, Mancuso AA, Amdur RJ and Werning JW: Laryngeal Cancer. In: Perez and Brady’s Principles and Practice of Radiation Oncology. 6th edition. Halperin EC, Perez CA and Brady LW (Eds.). Philadelphia: Lippincott William & Wilkins, pp. 850–868, 2013.

4 Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Villaret DB. Management of T1-T2 glottic carcinomas. Cancer. 2004;100(9):1786–1792. doi:10.1002/cncr.20181.

5 Reddy SP, Hong RL, Nagda S, Emami B. Effect of Tumor Bulk on Local Control and Survival of Patients With T1 Glottic Cancer: A 30-Year Experience. Int J Radiat Oncol Biol Phys. 2007;69(5):1389–1394. doi:10.1016/j.ijrobp.2007.05.077.

6 Jin J, Liao Z, Gao L, Huang X, Xu G. Analysis of prognostic factors for T1N0M0 glottic cancer treated with definitive radiotherapy alone: Experience of the cancer hospital of Peking Union Medical College and the Chinese Academy of Medical Sciences. Int J Radiat Oncol Biol Phys. 2002;54(2):471–478. doi:10.1016/ S0360-3016(02)02920-6.

7 Frata P, Cellai E, Magrini SM, et al. Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. II. The case of T2N0 disease. Int J Radiat Oncol Biol Phys. 2005;63(5):1387–1394. doi:10.1016/j.ijrobp.2005.05.013.

8 Harada K, Kawaguchi SI, Supriatno, Onoue T, Yoshida H, Sato M. Combined effects of the oral fluoropy- rimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol. 2004;40(7):713–719. doi:10.1016/j.oraloncology.2004.01.013.

9 Harada K, Kawaguchi S, Supriatno, Kawashima Y, Yoshida H, Sato M. S-1, an oral fluoropyrimidine anti- cancer agent, enhanced radiosensitivity in a human oral cancer cell line in vivo and in vitro: Involvement possibility of inhibition of survival signal, Akt/PKB. Cancer Lett. 2005;226(2):161–168. doi:10.1016/j. canlet.2004.12.048.

10 Zeng L, Ou G, Itasaka S, et al. TS-1 enhances the effect of radiotherapy by suppressing radiation-induced hypoxia-inducible factor-1 activation and inducing endothelial cell apoptosis. Cancer Sci. 2008;99(11):2327– 2335. doi:10.1111/j.1349-7006.2008.00943.x.

11 Fukushima M, Sakamoto K, Sakata M, Nakagawa F, Saito H, Sakata Y. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo. Oncol Rep. 2010;24(5):1307–1313. doi:10.3892/or_00000987.

12 Sakata K, Someya M, Matsumoto Y, et al. Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination. Cancer Sci. 2011;102(9):1712–1716. doi:10.1111/j.1349- 7006.2011.02004.x.

13 Fujimoto Y, Kato S, Itoh Y, Naganawa S, Nakashima T. A phase I study of concurrent chemoradiotherapy using oral S-1 for head and neck cancer. Anticancer Res. 2014;34(1):209–213.

14 Kimura K, Itoh Y, Okada T, et al. Critical evaluation of a prospective study of concurrent chemoradiotherapy with S-1 for early glottic carcinoma. Anticancer Res. 2015;35(4):2385–2390.

15 Sobin LH, eds. Cancer IU against: TNM Classification of Malignant Tumours. 6th ed. New York: Wiley-Liss; 2002.

16 Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7(5):548–557. doi:10.1097/00001813-199607000-00010.

17 Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol. 2003;13(1):13–21. doi:10.1053/srao.2003.50002.

18 Byfield JE, Calabro-Jones P, Klisak I, Kulhanian F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-Fluorouracil or ftorafur and X rays. Int J Radiat Oncol Biol Phys. 1982;8(11):1923–1933. doi:10.1016/0360-3016(82)90451-5.

19 Taguchi T, Inuyama Y, Kanamaru R, et al. Phase I study of S-1. S-1 Study Group[in Japanese]. Gan To Kagaku Ryoho. 1997;24(15):2253–2264.

20 Nonoshita T, Shioyama Y, Nakamura K, et al. Concurrent Chemoradiotherapy with S-1 for T2N0 Glottic Squamous Cell Carcinoma. J Radiat Res. 2010;51(4):481–484. doi:10.1269/jrr.09134.

21 Nakayama M, Hayakawa K, Okamoto M, Niibe Y, Ishiyama H, Kotani S. Phase I/II trial of concurrent use of S-1 and radiation therapy for T2 glottic cancer. Jpn J Clin Oncol. 2010;40(10):921–926. doi:10.1093/ jjco/hyq077.

22 Ikeda Y, Tsukuda M, Tanigaki Y, Yabuki K, Mitake D, Ishitoya J. Concurrent chemoradiotherapy with S-1 for T2N0 glottic carcinoma[in Japanese]. Gan To Kagaku Ryoho. 2008;35(5):789–792.

23 Itoh Y, Fuwa N. Retrospective analysis: Concurrent chemoradiotherapy using protracted continuous infu- sion of low-dose cisplatin and 5-fluorouracil for T2N0 glottic cancer. Radiat Med. 2006;24(4):277–281. doi:10.1007/s11604-005-1517-1.

24 Hirasawa N, Itoh Y, Ishihara S, et al. Radiotherapy with or without chemotherapy for patients with T1-T2 glottic carcinoma: Retrospective analysis. Head Neck Oncol. 2010;2:20. doi:10.1186/1758-3284-2-20.

25 Kodaira T, Kagami Y, Shibata T, et al. Results of a multi-institutional, randomized, non-inferiority, phase III trial of accelerated fractionation versus standard fractionation in radiation therapy for T1-2N0M0 glottic cancer: Japan Clinical Oncology Group Study (JCOG0701). Ann Oncol. 2018;29(4):992–997. doi:10.1093/ annonc/mdy036.

26 Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemo-therapy. J Clin Oncol. 1997;15(1):110–115. doi:10.1200/JCO.1997.15.1.110.

27 Greer JA, Amoyal N, Nisotel L, et al. A Systematic Review of Adherence to Oral Antineoplastic Therapies. Oncologist. 2016;21(3):354–376. doi:10.1634/theoncologist.2015-0405.

参考文献をもっと見る